Promoterless Gene Targeting Approach Combined to CRISPR/Cas9 Efficiently Corrects Hemophilia B Phenotype in Neonatal Mice
Michela Lisjak(International Centre for Genetic Engineering and Biotechnology), Andrés F. Muro(International Centre for Genetic Engineering and Biotechnology), Mark A. Kay(Io Therapeutics (United States)), Adi Barzel(Tel Aviv University), Alessia De Caneva(International Centre for Genetic Engineering and Biotechnology), Maria Grazia Biferi(Inserm), Elena Barbon(Vita-Salute San Raffaele University), Thibaut Marais(Inserm), Lorena Zentilin(National Center for Genetic Engineering and Biotechnology), Federico Mingozzi(Spark Therapeutics (United States)), Fabiola Porro(International Centre for Genetic Engineering and Biotechnology)
Cited by 23
Related Papers
Overcoming Preexisting Humoral Immunity to AAV Using Capsid Decoys
|Science Translational Medicine|2013|346
A bright cyan-excitable orange fluorescent protein facilitates dual-emission microscopy and enhances bioluminescence imaging in vivo
|Nature Biotechnology|2016|323
MiR-378 Controls Cardiac Hypertrophy by Combined Repression of Mitogen-Activated Protein Kinase Pathway Factors
|Circulation|2013|242
Whole body correction of mucopolysaccharidosis IIIA by intracerebrospinal fluid gene therapy
|Journal of Clinical Investigation|2013|232